Akums Drugs and Pharma climbs after strong Q2 earnings
Profit before tax (PBT) soared 135.63% YoY to Rs 154.74 crore in Q2 FY27. The company's EBITDA surged 106% YoY to Rs 195 crore compared with Rs 94 crore in the corresponding quarter last year. EBITDA margin expanded to 14.5% from 9.3%.
The CDMO business remained the key growth driver, with revenue increasing 38.6% YoY to Rs 1,115 crore from Rs 804 crore. CDMO EBITDA nearly doubled to Rs 168 crore from Rs 84 crore, supported by healthy double-digit volume growth and sustained demand.
For the first half of FY27, the company?s consolidated net profit surged 104.18% YoY to Rs 212.86 crore in H1 FY27, revenue from operations increased 22.9% to Rs 2,509.01 crore in H1 FY27 from Rs 2,041.56 crore in H1 FY26.
Sanjeev Jain, managing director, said, ?We remain committed to strengthening our position as India's largest CDMO player. The demand environment continues to remain robust, reflecting the growing importance of reliable manufacturing partners. We are continuously investing in our manufacturing infrastructure, and strengthening our capabilities to address the evolving requirements of our partners. Our focus remains on operational excellence, consistent quality and building long-term relationships based on trust.
Sandeep Jain, managing director, added, ?Our ambition is to establish Akums as a globally recognised CDMO player, with capabilities that extend across markets, dosage forms and therapeutic segments. We are working towards this vision by strengthening our product pipeline for global markets and expanding our manufacturing capabilities. With a robust pipeline of over 30 products for European markets, we see significant opportunities to broaden our offerings and deepen our engagement with global partners. Our focus is on building a diversified and sustainable business that combines manufacturing scale, formulation expertise and global quality standards to support our long-term growth aspirations.?
Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
Powered by Capital Market - Live News